Literature DB >> 9183483

Clinical use of acid steatocrit.

A Van den Neucker1, N Pestel, T M Tran, P P Forget, H J Veeze, J Bouquet, M Sinaasappel.   

Abstract

Malabsorption of fat is an important gastrointestinal cause of malnutrition and growth retardation in childhood. The gold standard for the evaluation of fat malabsorption is the faecal fat balance method. The acid steatocrit method has recently been introduced as a simple method to evaluate faecal fat. The present study was aimed at evaluating the acid steatocrit in clinical practice. Faecal fat excretion and acid steatocrit results were determined in 42 children, half with and half without fat malabsorption. Acid steatocrit results correlated significantly with both faecal fat excretion (p < 0.01) and faecal fat concentration (p < 0.001). Sensitivity and specificity of the acid steatocrit for the diagnosis of malabsorption were 90% and 100%, respectively. We consider the acid steatocrit method useful for the screening and monitoring of patients with steatorrhoea.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9183483     DOI: 10.1111/j.1651-2227.1997.tb08914.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

Review 1.  Control of malabsorption in cystic fibrosis.

Authors:  J M Littlewood; S P Wolfe
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

2.  Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid.

Authors:  Jill Dorsey; Donna Buckley; Suzanne Summer; Ronald J Jandacek; Therese Rider; Patrick Tso; Michael R Narkewicz; James E Heubi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-04       Impact factor: 2.839

3.  The steatocrit as a measure of fecal fat excretion: uses and pitfalls.

Authors:  B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2009-12

4.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

5.  Lipid, nitrogen, water and energy content of a single stool sample in healthy children and children with cystic fibrosis.

Authors:  Anita Maria Van den Neucker; Pierre-Philippe Forget; Bernard van Kreel
Journal:  Eur J Pediatr       Date:  2003-08-27       Impact factor: 3.183

6.  Simple and noninvasive method for assessment of digestive efficiency: Validation of fecal steatocrit in greenfinch coccidiosis model.

Authors:  Richard Meitern; Mari-Ann Lind; Ulvi Karu; Peeter Hõrak
Journal:  Ecol Evol       Date:  2016-11-17       Impact factor: 2.912

7.  Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure.

Authors:  Hillary S Hayden; Alexander Eng; Christopher E Pope; Mitchell J Brittnacher; Anh T Vo; Eli J Weiss; Kyle R Hager; Bryan D Martin; Daniel H Leung; Sonya L Heltshe; Elhanan Borenstein; Samuel I Miller; Lucas R Hoffman
Journal:  Nat Med       Date:  2020-01-20       Impact factor: 53.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.